U.S. markets open in 3 minutes

OraSure Technologies, Inc. (OSUR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.10-0.56 (-4.80%)
At close: 4:00PM EST

11.02 -0.08 (-0.72%)
Before hours: 8:33AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close11.66
Open11.65
Bid11.03 x 1000
Ask11.22 x 800
Day's Range11.01 - 11.65
52 Week Range5.23 - 19.75
Volume1,694,040
Avg. Volume2,157,383
Market Cap796.234M
Beta (5Y Monthly)0.29
PE Ratio (TTM)N/A
EPS (TTM)-0.22
Earnings DateFeb 17, 2021 - Feb 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-40% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • OraSure Technologies to Present at the Stephens Annual Investment Conference 2020
    GlobeNewswire

    OraSure Technologies to Present at the Stephens Annual Investment Conference 2020

    BETHLEHEM, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the Stephens Annual Investment Conference 2020. The conference will be simultaneously webcast over the Internet. Dr. Tang is scheduled to speak on November 19, 2020, at approximately 8:00 AM Eastern Standard Time (5:00 AM Pacific Time). Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site, www.orasure.com and clicking on the Investor Info link. A replay of the webcast will be available on OraSure Technologies’ web site for seven days. Alternatively, you can access the live webcast of the presentation via the following link: https://kvgo.com/stephens/orasure-november-2020 About OraSure TechnologiesOraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, CoreBiome (now operating under the Diversigen brand), UrSure and Novosanis, OraSure provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.Company contacts: Sam Martin Argot Partners 212-600-1902 OraSure@argotpartners.comJeanne Mell VP Corporate Communications 484-353-1575 media@orasure.com www.orasure.com

  • Stock Upgrades: Orasure Technologies Shows Rising Relative Strength
    Investor's Business Daily

    Stock Upgrades: Orasure Technologies Shows Rising Relative Strength

    Orasure Technologies just met that criteria with a new score of 85. When looking for the best stocks to buy and watch, keep a close on eye on relative price strength. Orasure Technologies earns the No. 51 rank among its peers in the Medical-Products industry group.

  • Clinical Reference Laboratory to Market Most Cost-Effective, Gold-Standard Self-Collected COVID-19 Saliva Test Directly to Consumers
    PR Newswire

    Clinical Reference Laboratory to Market Most Cost-Effective, Gold-Standard Self-Collected COVID-19 Saliva Test Directly to Consumers

    Today, Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., announced that it has begun selling its best-in-class CRL Rapid Response™ saliva-based COVID-19 RT-PCR test directly to consumers. At $110 (which includes the cost of prepaid FedEx Priority Overnight shipping in both directions), the easy-to-use, highly accurate test is one of the most affordable COVID-19 home tests currently available in the market and the least expensive at-home saliva test.